2554 related articles for article (PubMed ID: 26106858)
1. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Melo SA; Luecke LB; Kahlert C; Fernandez AF; Gammon ST; Kaye J; LeBleu VS; Mittendorf EA; Weitz J; Rahbari N; Reissfelder C; Pilarsky C; Fraga MF; Piwnica-Worms D; Kalluri R
Nature; 2015 Jul; 523(7559):177-82. PubMed ID: 26106858
[TBL] [Abstract][Full Text] [Related]
2. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
Moutinho-Ribeiro P; Batista IA; Quintas ST; Adem B; Silva M; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Medas R; Lopes S; Vilas-Boas F; Baptista M; Dias-Silva D; Esteves AL; Martins F; Lopes J; Barroca H; Carneiro F; Macedo G; Melo SA
World J Gastroenterol; 2022 Aug; 28(31):4310-4327. PubMed ID: 36159010
[TBL] [Abstract][Full Text] [Related]
3. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
Frampton AE; Prado MM; López-Jiménez E; Fajardo-Puerta AB; Jawad ZAR; Lawton P; Giovannetti E; Habib NA; Castellano L; Stebbing J; Krell J; Jiao LR
Oncotarget; 2018 Apr; 9(27):19006-19013. PubMed ID: 29721179
[TBL] [Abstract][Full Text] [Related]
4. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
[TBL] [Abstract][Full Text] [Related]
5. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer.
Xiao D; Dong Z; Zhen L; Xia G; Huang X; Wang T; Guo H; Yang B; Xu C; Wu W; Zhao X; Xu H
Mol Cancer Res; 2020 Feb; 18(2):300-310. PubMed ID: 31662449
[TBL] [Abstract][Full Text] [Related]
6. Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy.
Hingorani SR
Cancer Cell; 2015 Aug; 28(2):151-3. PubMed ID: 26267532
[TBL] [Abstract][Full Text] [Related]
7. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer.
Herreros-Villanueva M; Bujanda L
Ann Transl Med; 2016 Feb; 4(4):64. PubMed ID: 27004211
[TBL] [Abstract][Full Text] [Related]
8. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
[TBL] [Abstract][Full Text] [Related]
9. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
10. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer.
Li J; Chen Y; Guo X; Zhou L; Jia Z; Peng Z; Tang Y; Liu W; Zhu B; Wang L; Ren C
J Cell Mol Med; 2017 May; 21(5):838-847. PubMed ID: 28233416
[TBL] [Abstract][Full Text] [Related]
11. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.
Kahlert C; Melo SA; Protopopov A; Tang J; Seth S; Koch M; Zhang J; Weitz J; Chin L; Futreal A; Kalluri R
J Biol Chem; 2014 Feb; 289(7):3869-75. PubMed ID: 24398677
[TBL] [Abstract][Full Text] [Related]
12. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
[TBL] [Abstract][Full Text] [Related]
13. Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation.
Yan S; Zheng H; Zhao J; Gao M; Zhang X
Anal Chem; 2023 Jul; 95(27):10196-10203. PubMed ID: 37368911
[TBL] [Abstract][Full Text] [Related]
14. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
[TBL] [Abstract][Full Text] [Related]
15. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
[TBL] [Abstract][Full Text] [Related]
16. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis.
Li H; Chiang CL; Kwak KJ; Wang X; Doddi S; Ramanathan LV; Cho SM; Hou YC; Cheng TS; Mo X; Chang YS; Chang HL; Cheng W; Tsai WN; Nguyen LTH; Pan J; Ma Y; Rima XY; Zhang J; Reategui E; Chu YS; Chang PM; Chang PH; Huang CF; Wang CH; Shan YS; Li CP; Fleisher M; Lee LJ
Adv Sci (Weinh); 2024 Mar; 11(11):e2306373. PubMed ID: 38204202
[TBL] [Abstract][Full Text] [Related]
17. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
19. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Lux A; Kahlert C; Grützmann R; Pilarsky C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284422
[TBL] [Abstract][Full Text] [Related]
20. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Kamerkar S; LeBleu VS; Sugimoto H; Yang S; Ruivo CF; Melo SA; Lee JJ; Kalluri R
Nature; 2017 Jun; 546(7659):498-503. PubMed ID: 28607485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
